Cannamore Biotechs
Cannabis-based Treatment Solutions
Company Overview
Snapshot
Founded in October 2018 by David Bassa, Cannamore Biotechs operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on preclinical and clinical research for cannabis-based treatments.
Business overview
Cannamore Biotechs is a preclinical and clinical-stage research platform company dedicated to developing novel and improved cannabis-based treatment options. The company's core technology focuses on CBD-based solutions for conditions such as bronchiolans, peripheral neuropathy, and inflammatory bowel diseases. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Medical Cannabis, Cannamore Biotechs serves the healthcare and life sciences industries globally, targeting biotechnology, pharmaceuticals, and laboratories.
Strategic signal
In September 2022, Cannamore Biotechs was featured in an article highlighting its efforts in driving medical cannabis-based therapies forward with biotechnology. This signals the company's commitment to advancing the therapeutic potential of cannabis and its strategic positioning within the evolving medical cannabis market, indicating a focus on R&D and clinical validation to attract future investment and partnerships.
Company Intelligence Q&A
- What is Cannamore Biotechs' primary focus?
- Cannamore Biotechs is a preclinical and clinical-stage research platform company committed to developing novel and improved cannabis-based treatment options for conditions such as bronchiolans, peripheral neuropathy, and inflammatory bowel diseases.
- When was Cannamore Biotechs founded?
- Cannamore Biotechs was founded in October 2018.
- Who is the founder of Cannamore Biotechs?
- David Bassa is the founder of Cannamore Biotechs.
- What is the current employee size of Cannamore Biotechs?
- Cannamore Biotechs currently has 1–10 employees.
- What is Cannamore Biotechs' current funding stage?
- Cannamore Biotechs is currently in the Pre-Funding stage, indicating it has not yet secured external investment rounds.